Market capitalization | $421.11m |
Enterprise Value | $239.43m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.53 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-49.76m |
Free Cash Flow (TTM) Free Cash Flow | $-50.91m |
Cash position | $185.12m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
4 Analysts have issued a AVROBIO Inc forecast:
4 Analysts have issued a AVROBIO Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.26 -0.26 |
95%
95%
|
|
EBITDA | -49 -49 |
41%
41%
|
EBIT (Operating Income) EBIT | -50 -50 |
44%
44%
|
Net Profit | -50 -50 |
809%
809%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firms clinical-stage programs include Fabry disease, Gaucher disease and cystinosis . The company was founded by Geoff Mackay in 2015 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Alise Reicin |
Employees | 13 |
Founded | 2015 |
Website | tectonictx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.